Hologic (HOLX) Rating Reiterated by Royal Bank of Canada


's stock had its "hold" rating restated by research analysts at Royal Bank of Canada in a research report issued on Friday. They presently have a $44.00 price objective on the medical equipment provider's stock.



from Biotech News